PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
For the period ended Dec 31, 2025. Filed Feb 25, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 25, 2026
PACB$2.36+4.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Exhibit Index
| Incorporated by reference herein | ||||
|---|---|---|---|---|
| ExhibitNumber | Description | Form | Exhibit No. | Filing Date |
| 3.1 | Amended and Restated Certificate of Incorporation | 10-K | 3.1 | March 23, 2011 |
| 3.2 | Third Amended and Restated Bylaws of Pacific Biosciences of California, Inc. | 8-K | 3.1 | November 7, 2022 |
| 3.3 | Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Pacific Biosciences of California, Inc. to declassify the Board | 8-K | 3.1 | June 20, 2024 |
| 3.4 | Certificate of Amendment to the Certificate of Incorporation of Pacific Biosciences of California, Inc. to limit the liability of officers | 8-K | 3.2 | June 20, 2024 |
| 4.1 | Specimen Common Stock Certificate | S-1/A | 4.1 | October 1, 2010 |
| 4.2 | Description of Registrant’s securities registered under Section 12 of the Exchange Act | Filed herewith | ||
| 4.3 | Indenture, dated February 16, 2021, between Pacific Biosciences of California, Inc., and U.S. Bank National Association, as Trustee | 10-Q | 4.1 | August 4, 2023 |
| 4.4 | Form of 1.50% Convertible Senior Notes due 2028 (included in Exhibit 4.3) | 10-Q | 4.1 | August 4, 2023 |
| 4.5 | Indenture, dated as of June 30, 2023, by and between Pacific Biosciences of California, Inc. and U.S. Bank Trust Company, National Association, as Trustee | 8-K | 4.1 | June 30, 2023 |
| 4.6 | Form of 1.375% Convertible Senior Note due 2030 (included in Exhibit 4.5) | 8-K | 4.2 | June 30, 2023 |
| 4.7 | Indenture, dated as of November 21, 2024, by and between Pacific Biosciences of California, Inc. and U.S. Bank Trust Company, National Association, as Trustee. | 8-K | 4.1 | November 22, 2024 |
| 4.8 | Form of 1.50% Convertible Senior Note due 2029 (included in Exhibit 4.7) | 8-K | 4.2 | November 22, 2024 |
| 10.1+ | Form of Director and Executive Officer Indemnification Agreement | S-1 | 10.1 | August 16, 2010 |
| 10.2+ | 2010 Equity Incentive Plan | S-1 | 10.4 | August 16, 2010 |
| 10.3+ | 2010 Equity Incentive Plan forms of agreement | 10-Q | 10.1 | May 2, 2018 |
| 10.4+ | 2010 Employee Stock Purchase Plan and forms of agreement thereunder | S-1 | 10.5 | August 16, 2010 |
| 10.5+ | 2010 Outside Director Equity Incentive Plan | S-1 | 10.6 | August 16, 2010 |
| 10.6+ | 2010 Outside Director Equity Incentive Plan forms of agreement | 10-Q | 10.2 | May 2, 2018 |
| 10.7+ | 2020 Equity Incentive Plan, as amended | 8-K | 10.1 | June 6, 2025 |
| 10.8+ | Form of Global Stock Option Agreement under the Pacific Biosciences of California, Inc., 2020 Equity Incentive Plan, as amended | 8-K | 10.2 | June 20, 2024 |
| 10.9+ | Form of Global Restricted Stock Unit Agreement under the Pacific Biosciences of California, Inc. 2020 Equity Incentive Plan, as amended | 8-K | 10.3 | June 20, 2024 |
| 10.10+ | Omniome Equity Incentive Plan of Pacific Biosciences of California, Inc., and related forms of agreement thereunder | 10-Q | 10.4 | November 5, 2021 |
| 10.11+ | Pacific Biosciences of California, Inc. 2020 Inducement Equity Incentive Plan, as amended, and forms of agreement thereunder | 8-K | 10.1 | November 19, 2021 |
| 10.12+ | Form of Change in Control and Severance Agreement for executive officers | 10-K | 10.13 | March 17, 2025 |
| 10.13+ | Letter Relating to Employment Terms by and between the Registrant and Christian O. Henry effective September 14, 2020 | 10-K | 10.15 | February 26, 2021 |
| 10.14+ | Amended Change in Control and Severance Agreement by and between the Registrant and Christian O. Henry dated December 11, 2024 | 10-K | 10.15 | March 17, 2025 |
| 10.15+ | Letter Relating to Employment Terms by and between the Registrant and Mark Van Oene effective January 8, 2021 | 10-K | 10.18 | February 26, 2021 |
| 10.16+ | Amended Change in Control and Severance Agreement by and between the Registrant and Mark Van Oene dated December 12, 2024 | 10-K | 10.17 | March 17, 2025 |
| 10.17† | Lease Agreement by and between the Registrant and Menlo Park Portfolio II, LLC, dated July 22, 2015 | 10-K | 10.18 | March 17, 2025 |
| 10.18† | First Amendment to Lease Agreement by and between the Registrant and Menlo Park Portfolio II, LLC, dated December 23, 2016 | 10-K | 10.19 | March 17, 2025 |
| 10.19 | Second Amendment to Lease Agreement by and between the Registrant and Menlo Park Portfolio II, LLC, dated December 30, 2019 | 10-K | 10.20 | March 17, 2025 |
| 10.20 | Third Amendment to Lease Agreement by and between the Registrant and Menlo Park Portfolio II, LLC, dated March 7, 2025 | 10-K | 10.21 | March 17, 2025 |
| 10.21 | Investment Agreement, dated as of February 9, 2021, between Pacific Biosciences of California, Inc. and SB Northstar LP. | 8-K | 10.1 | February 10, 2021 |
| 10.22+ | Letter Relating to Employment Terms by and between the Registrant and Michele Farmer effective May 17, 2021 | 10-Q | 10.2 | August 6, 2021 |
| 10.23 | Agreement and Plan of Merger of Reorganization among Pacific Biosciences of California, Inc., Apollo Acquisition Corp., Apollo Acquisition Sub, LLC, Omniome, Inc. and Shareholder Representative Services, LLC, as securityholder representative, dated as of July 19, 2021 | 8-K | 10.1 | July 20, 2021 |
| 10.24 | Securities Purchase Agreement, dated as of July 19, 2021, by and between Pacific Biosciences of California, Inc., and each of the Investors | 8-K | 10.2 | July 20, 2021 |
| 10.25 | Letter Agreement, dated June 23, 2023, between the Company and Chimera Investment LLC | 8-K | 10.1 | June 26, 2023 |
| 10.26 | Letter Agreement, dated November 7, 2024, between the Company and SB Northstar LP | 8-K | 10.1 | November 7, 2024 |
| 10.27 | Letter Agreement, dated November 21, 2024, between the Company and SB Northstar LP | 8-K | 10.1 | November 22, 2024 |
| 10.28+ | Form of Performance-Based Restricted Stock Unit Award Agreement under the Pacific Biosciences of California, Inc. 2020 Equity Incentive Plan, as amended | 10-K | 10.28 | February 28, 2024 |
| 10.29+ | Outside Director Compensation Policy | 10-Q | 10.3 | May 12, 2025 |
| 10.30+ | Letter Relating to Employment Terms by and between the Registrant and James R. Gibson effective March 24, 2025 | 10-Q | 10.2 | May 12, 2025 |
| 10.31+ | Asset Purchase Agreement, dated January 30, 2026, by and between the Company, Illumina Cambridge Limited, and Illumina, Inc. | 8-K | 10.1 | February 2, 2026 |
| 10.32+ | Executive Incentive Compensation Plan | Filed herewith | ||
| 19.1 | Insider Trading Policy | 10-K | 19.1 | March 17, 2025 |
| 21.1 | List of Subsidiaries of the Registrant | Filed herewith | ||
| 23.1 | Consent of Independent Registered Public Accounting Firm | Filed herewith | ||
| 31.1 | Certification of Chief Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | Filed herewith | ||
| 31.2 | Certification of Chief Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | Filed herewith | ||
| 32.1* | Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | Furnished herewith | ||
| 32.2* | Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | Furnished herewith | ||
| 97.1 | Compensation Recovery Policy | 10-K | 97.1 | February 28, 2024 |
| 101.INS | XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document) | Filed herewith | ||
| 101.SCH | XBRL Taxonomy Extension Schema Document | Filed herewith | ||
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document | Filed herewith | ||
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase Document | Filed herewith | ||
| 101.LAB | XBRL Taxonomy Extension Labels Linkbase Document | Filed herewith | ||
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document | Filed herewith |
| 104 | Cover Page Interactive File (formatted as inline XBRL and contained in Exhibit 101) | Filed herewith |
| + | Indicates management contract or compensatory plan. |
|---|---|
| † | Certain confidential information contained in this Exhibit was omitted by means of marking such portions with brackets because (i) the identified confidential information is not material and (ii) the company customarily and actually treats that information as private or confidential. |
| * | The certifications attached as Exhibit 32.1 and 32.2 that accompany this Annual Report on Form 10-K are deemed furnished and not filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of Pacific Biosciences of California, Inc. under the Securities Act or the Exchange Act, whether made before or after the date of this Annual Report on Form 10-K, irrespective of any general incorporation language contained in such filing. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.